• Policy
• FDA

Peptide Week in 5 minutes: HHS opens a door for six peptides (October 26 to November 1, 2026)

By Peptide Policy Watch staff · Published November 1, 2026 · 7 min read · 17 sources, 16 checked at the source

If you only caught one peptide headline this week, it was probably this one: HHS published a policy that lets licensed pharmacies and physicians compound BPC-157, TB-500, epitalon, KPV, MOTS-c and semax while FDA's rulemaking plays out. It's the biggest access move we've covered since the site launched. Below is the week in order, what it changes, and the few things still open.

Facts are as of November 1, 2026. Sources, with retrieval dates, are at the bottom.

Day by day

• Monday, Oct 26. Novo Nordisk filed a Form 6-K with the SEC. It covers its share buyback and nothing on peptides or compounding. [V]
• Tuesday, Oct 27. OMB's record for RIN 0910-ZD94 shows the review closed that day. That's the "Interim Access Policy for Compounding Using Certain Peptides" HHS sent over on October 14. [V] FDA also posted a batch of warning letters dated 10/27; none of the subject lines we read named a peptide. [V]
• Wednesday, Oct 28. The policy text went on the Federal Register's public inspection desk as document 2026-22192. [V] Lilly reported first results from a phase 3 trial that pitted retatrutide directly against Ozempic in adults with type 2 diabetes; we covered it here. [V]
• Thursday, Oct 29. Lilly's third-quarter 8-K reported revenue up 39% to $24.4 billion, driven mainly by Mounjaro and Zepbound. [V]
• Friday, Oct 30. Publication day: 91 FR 68526, plus a new docket, HHS-OASH-2026-0496. [V]
• Saturday and Sunday. Quiet. We re-checked FDA's compounding pages and found no new dates. [V]

What the policy actually does

Here's the core of it. Until a final rule settles whether each of the six goes on the 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry bulks list, HHS says it won't pursue enforcement when they are compounded by a pharmacy or doctor licensed by a state, or by a federal facility, as long as ten conditions are met. [V] Those conditions lean on quality paperwork: an original manufacturer registered with FDA, a valid certificate of analysis for the bulk ingredient, one active ingredient per product, a label reading "This is a compounded drug product. Not for resale," and MedWatch reporting of serious adverse events. [V] A valid patient-specific prescription is still required. [V]

HHS's reasoning, set out peptide by peptide in Appendix B, is worth a read. For KPV, it says historical use is now documented and quantified, where FDA's drug center had called the extent of use unknown. For TB-500, epitalon and semax, it describes the drug center's safety concerns as inferential or mechanistic rather than observed. [V] We checked those reasons against the published research in a separate piece, and our brief on the policy walks through all ten conditions.

How the timeline moved

On our cornerstone timeline, the "interim policy" line went from reported, under White House review to published, in force, open for comment. That's one status change in seven days, and it's a big one. The six peptides now carry "Covered by HHS's interim 503A policy" on our policy tracker. [V] Nothing else on the timeline changed. FDA's 503A bulks page still reads current as of 05/14/2026, the category list PDF still says "Updated May 14, 2026," and the 503B bulks page is still at 01/07/2025. [V]

Still open

1. The comment window. It closes November 13. HHS says comments "may provide additional evidence" FDA can use in rulemaking. [V] Our comment-period explainer shows how it works.
2. FDA's rulemaking on the six. The policy lasts until a final rule decides each one. No proposed rule has appeared. [V]
3. A final 503B call on semaglutide, tirzepatide and liraglutide. Our Federal Register search turned up nothing new this week. [V]
4. FDA's next compounding advisory meeting, which FDA says will take place before the end of February 2027 with LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF on the agenda. Still no date and no notice. [V] Background is in our preview.
5. FTC v. Hims & Hers. The FTC's case page still says "Pending." A court-docket aggregator lists responses to the motion to dismiss as due November 25, with a hearing on January 7, 2027. [S] We haven't opened the filings.

Next week's short list

• The posted-comment count on the docket, which we refresh each night. [V]
• Any FDA statement on how it will handle the six in rulemaking.
• The Federal Register, for a 503B decision on the GLP-1 drugs or a notice for the next advisory meeting.

What this week does and doesn't settle

The policy is a real access change for six peptides, but it's enforcement discretion, not approval. FDA hasn't approved any of the six as a drug, and none is on the 503A bulks list yet. [V] HHS says it may revisit the policy if a safety signal or quality problem shows up. [V] What it does establish is that, for now, a licensed compounder meeting the conditions has a written federal policy to point to. Whether that becomes permanent comes down to rulemaking, and that's what we'll be watching most closely.

Sources (retrieved November 1, 2026 unless noted)

1. HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," with Appendices A and B (PDF) [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
2. Federal Register, 91 FR 68526 (FR Doc. 2026-22192), published October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
3. Federal Register public inspection, document 2026-22192, retrieved October 28, 2026 [V] — https://public-inspection.federalregister.gov/2026-22192.pdf
4. OMB/OIRA, Conclusion of EO 12866 Regulatory Review, RIN 0910-ZD94 (received 10/14/2026, concluded 10/27/2026, "Consistent with Change") [V] — https://www.reginfo.gov/public/do/eoDetails?rrid=1569111
5. Regulations.gov docket HHS-OASH-2026-0496 and public data service comment search (0 posted at 2:24 AM CT, November 1, 2026; documents 0001 and 0002 open until 11:59 PM Eastern, November 13) [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
6. SEC, Eli Lilly Form 8-K, Exhibit 99, October 29, 2026 [V] — https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/
7. SEC, Novo Nordisk Form 6-K, October 26, 2026 [V] — https://www.sec.gov/Archives/edgar/data/353278/000117184326006813/f6k_102626.htm
8. FDA, Warning Letters page (postings dated 10/27/2026) [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
9. FDA, 503A bulks page, content current as of 05/14/2026 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
10. FDA, 503A category list (PDF), "Updated May 14, 2026" [V] — https://www.fda.gov/media/94155/download
11. FDA, 503B bulks page, content current as of 01/07/2025 [V] — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act
12. FDA, Pharmacy Compounding Advisory Committee early announcement, content current as of 04/15/2026 [V] — https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee
13. Federal Register API searches ("503B", "bulk drug substances", "compounding", "peptide", "GLP-1"), documents published since October 25, 2026 [V] — https://www.federalregister.gov/api/v1/documents.json
14. FTC, Hims & Hers case page ("Pending"; last updated August 31, 2026) [V] — https://www.ftc.gov/legal-library/browse/cases-proceedings/hims-hers
15. PacerMonitor (secondary; mirrors the court docket), N.D. Cal. 3:26-cv-07871, retrieved October 25, 2026 [S] — https://www.pacermonitor.com/public/case/65961048/Federal_Trade_Commission_et_al_v_Hims__Hers_Health,_Inc
16. ClinicalTrials.gov, NCT07437547 record (estimated primary completion February 14, 2027) [V] — https://clinicaltrials.gov/study/NCT07437547
17. Lilly, TRANSCEND-T2D-2 topline release, October 28, 2026, retrieved October 29, 2026 [V] — https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more

Spot a mistake? See how we source and our corrections policy.